NSRX · Nasus Pharma Ltd.

Summary

Nasus Pharma Ltd. announced positive top-line results from its Phase 2 clinical study of NS002 intranasal epinephrine powder, achieving significantly faster time to 100 pg/mL therapeutic threshold (median 1.69 minutes vs 3.42 minutes for EpiPen®, p=0.033) and higher early absorption. The company plans to initiate a pivotal study in Q4 2026.

Key takeaways

• NS002 median T100 of 1.69 minutes vs 3.42 minutes for EpiPen® (p=0.033)
• At 5 minutes, 88.4% NS002 subjects reached threshold vs 64.6% EpiPen® (p=0.0081)
• NS002 Tmax median 15 minutes vs 19.8 minutes EpiPen®
• 50% higher epinephrine absorption in first 10 minutes with NS002
• No serious adverse events reported for NS002
• Pivotal study initiation planned for Q4 2026